

What is claimed is

1. Use of a Checkpoint kinase 1 (Chk1) inhibitor in the manufacture of a medicament for treating cancer in a subject, wherein a therapeutically effective amount of the Chk1 inhibitor is to be administered to the subject identified as having cancer cells with a genetic abnormality in one or more genes selected from cell cycle regulation genes, replication stress genes, DNA damage response and repair network genes, and oncogenic driver genes, wherein the Chk1 inhibitor is SRA737 and wherein the subject is identified as having cancer lacking a RAS mutation.

~~2. The use of claim 1, wherein the genetic abnormality is an alteration, amplification, overexpression, or underexpression of the one or more genes.~~

23. The use of claim 1 ~~or 2~~, wherein (i) the one or more genes are selected from cell cycle regulation genes associated with the G1/S checkpoint and/or the p53 pathway;

~~4. The use of claim 1, wherein (ii) the one or more genes are selected from MDM2, TP53, RB1, CDKN1A/B and CDKN2A/B/C; or~~

~~5. The use of claim 1 or 2, wherein (iii) the one or more genes are selected from replication stress genes implicated in Chk1 pathway sensitivity, optionally;~~

~~6. The use of claim 5, wherein the one or more genes is selected from *Chk1* and *ATR*.~~

37. The use of claim 1 ~~or 2~~, wherein the one or more genes are selected from DNA damage response and repair genes associated with homologous recombination (HR), nonhomologous end joining (NHEJ), Fanconi anemia (FA), or mismatch repair, and a gene encoding chromatin or DNA polymerase;

~~8. The use of claim 7, optionally wherein the one or more genes is selected from *PALB2*, *ATM*, *BRCA1/A2*, *RAD51B*, *RAD51C*, *PRKDC*, *CDK12*, *FANCA*, *FANCD2*, *FANCE*, *FANCG*, *FANCI*, *FANCM*, *RAD52*, *RAD50*, *RAD51C*, *RAD54L*, *MLL2*, *ARID1A*, *ARID1B*, *MLH1*, *MSH2*, *MSH6*, *PMS2*, *POLD1*, and *POLE*.~~

49. The use of claim 1 ~~or 2~~, wherein the one or more genes are oncogenic driver genes of the following subclasses: CCNE, MYC and PI3K/AKT.

~~510.~~ The use of claim [49](#), wherein the one or more genes are of the CCNE subclass and selected from *CCNE1*, *FBXW7*, and *PARK2*; ~~or:~~

~~11.~~ ~~The use of claim 9,~~ wherein the one or more genes are of the MYC subclass and selected from *MYC*, *MYCN*, and *MYCL1*; ~~or:~~

~~12.~~ ~~The use of claim 9,~~ wherein the one or more genes are of the PI3K/AKT subclass and selected from *PIK3CA*, *PTEN*, *AKT1*, *AKT2*, and *AKT3*.

[6.](#) [The use of any one of claims 1 to 5, wherein the cancer is a squamous cell carcinoma; or wherein the cancer is selected from advanced / metastatic squamous cell carcinoma of the anus, penis, vagina, and vulva; or](#)

[wherein the cancer is selected from anogenital, rectal, ovarian, and cervical.](#)

[7.](#) [The use of claim 6, wherein the cancer is ovarian, optionally wherein the ovarian cancer is high-grade serious ovarian cancer \(HGSOC\).](#)

[8.](#) [The use of any one of the preceding claims, wherein the SRA737 compound is administered orally; optionally](#)

[wherein the SRA737 compound is administered daily, or](#)

[wherein the SRA737 compound is administered every other week, or](#)

[wherein the SRA737 compound is administered intermittently.](#)

[9.](#) [The use of any one of the preceding claims, wherein the effective amount is 1000 mg/day or less; or](#)

[wherein the effective amount is between 300 mg/day and 1000 mg/day; or](#)

[wherein the effective amount is selected from: 300 mg/day, 400 mg/day, 500 mg/day, 600 mg/day, 700 mg/day, 800 mg/day, 900 mg/day, and 1000 mg/day.](#)

[10.](#) [The use of any one of the preceding claims, further comprising administering gemcitabine to the subject in combination with the Chk1 inhibitor; optionally wherein an effective amount of the gemcitabine administered is sub-therapeutic.](#)

[11.](#) [The use of any one of the preceding claims, further comprising administering an immune checkpoint inhibitor to the subject, wherein the immune checkpoint inhibitor is a monoclonal](#)

antibody, wherein the monoclonal antibody is an anti-PD-1 or anti-PD-L1 antibody or an anti-CTLA-4 antibody.

~~13. —The use of claim 7, wherein the one or more genes is selected from DNA damage response and repair genes of the FA/BRCA replication fork subclass.~~

~~14. —The use of claim 13, wherein the one or more genes of the FA/BRCA replication fork subclass is selected from *BRCA1/2*, *RAD51B*, *RAD51C*, *PRKDC*, *CDK12*, *FANCA*, *FANCD2*, *FANCE*, *FANCG*, *FANCI*, *FANCM*, *RAD52*, *RAD50*, *RAD51C*, and *RAD54L*.~~